Yu. V. Roumiantseva

Yu. V. Roumiantseva

Auto-generated profile, based on publicly available information

Yu. V. Roumiantseva

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
DLD. V. Litvinov
D. V. Litvinov
ITI. P. Tesakov
I. P. Tesakov
LSL. N. Shelikhova
L. N. Shelikhova
LKL. A. Khachatryan
L. A. Khachatryan
EZE. A. Zerkalenkova
E. A. Zerkalenkova
ЮРЮ. В. Румянцева
Ю. В. Румянцева
Acute lymphoblastic leukemia (ALL) with translocation t(17;19)(q21-q22;p13) TCF3::HLF (E2A::HLF) accounts for less than 1% of childhood B-lineage ALL. Since the first description, patients with this type of ALL are stratified into high-risk group. The disease often has a unique clinical presentation with disseminated intravascular coagulation and hypercalcemia, that are uncommon in other types of B-lineage ALL. This type of ALL is characterized by an extremely poor prognosis despite intensive treatment and hematopoietic stem cell transplantation (HSCT) in the first remission. In the last decade, some new data on the mechanisms of leukemogenesis in this type of ALL made it possible to come closer to understanding the reasons for the high refractoriness to chemotherapeutic agents. Along with the reports on the possible effectiveness of the BCL-2 (venetoclax) and Aurora kinase A (alisertib) inhibitors in this type of ALL, cellular immunotherapy (various chimeric antigen receptor (CAR)-T cell constructs), anti-CD19 (blinatumomab) and anti-CD22 (inotuzumab ozogamicin) monoclonal antibodies appear promising in the treatment of this disease. To date, there are neither published data on direct comparisons of the effectiveness of these methods nor specific recommended therapy protocols for these patients. It is also unclear if the new therapeutic approaches can completely replace HSCT or they only increase relapse-free survival after it. Here, we review the data on this translocation published in the medical literature and present a case report of a 3-year-old boy with this type of leukemia, who did not respond to four-component induction therapy according to the ALL-MB 2015 Protocol and received anti-CD19 CAR-T therapy with the achievement of the first MRD (minimal residual disease)-negative remission, which lasted 11 months. After MRD-relapse and unsuccessful attempt at therapy with autologous CD19/CD22 CAR-T cells, the patient developed an extended isolated bone marrow relapse. He achieved the second MRD-negative remission after reinduction therapy with inotuzumab ozogomycin and received allogeneic HSCT from a related donor. At the time of writing, the patient is in complete molecular remission for 16 months after transplantation. The patient's parents have consented to the use of de-identified clinical information and photos of the patient in scientific research and publications.

14 April 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
RSR. N. Suprun
R. N. Suprun
YRYu. V. Roumiantseva
Yu. V. Roumiantseva
OBO. I. Bydanov
O. I. Bydanov
LZL. I. Zharikova
L. I. Zharikova
SLS. N. Lagoiko
S. N. Lagoiko
AKA. I. Karachunskiy
A. I. Karachunskiy
Down syndrome (DS) is one of the most common chromosomal abnormalities. Children with DS are more likely to develop acute lymphoblastic leukemia (ALL). Standard therapy is usually used to treat DS-ALL, but children with DS-ALL have an inferior outcome compared to non-DS patients, mainly due to increased therapy toxicity. The purpose of the study: in this study we aimed to analyze our experience of treating DS-ALL according to original protocol “Moscow–Berlin”. This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The analysis included primary ALL patients, aged 1 to 18 years, who received therapy in Russian and Belarusian clinics participating in the “Moscow–Berlin” study from January 2008 to December 2020. To analyze the treatment results of SD-ALL patients, a comparison group was formed from all patients with ALL registered in the database, using the matched-pair method. A total of 8296 ALL patients were registered in the database, of which 135 (1.63%) were patients with DS-ALL. The predominant age group of DS-ALL patients is 3–10 years. Among them there was no T-cell ALL patient, and both favorable and unfavorable genetic abnormalities were significantly less common. There were no differences in early response between DS-ALL and non-DS-ALL patients. The event-free (61 ± 6%) and overall survival (74 ± 4%) of DS-ALL patients was significantly lower than in the comparison group (84 ± 3% and 89 ± 3% respectively; p 0.001). No differences were found in relapse rate, while the treatment-related mortality (TRM) was higher in DS-ALL group (19.3 ± 3.5% versus 3.9 ± 1.2%; p˂0.001) in all treatment phase. The treatment results for DS-ALL patients remain unsatisfactory; therefore, new approaches to optimizing therapy are needed. High toxicity and associated TRM are the main problem. Future strategies to improve outcome in DS-ALL should include improved supportive care, the use of targeted drugs and immunotherapy, as well as the identification of new molecular genetic features.

8 November 2022 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
RSR. N. Suprun
R. N. Suprun
YRYu. V. Rumyantseva
Yu. V. Rumyantseva
OBO. I. Bydanov
O. I. Bydanov
LZL. I. Zharikova
L. I. Zharikova
SLS. N. Lagoiko
S. N. Lagoiko
AKA. I. Karachunskiy
A. I. Karachunskiy
Introduction. Down syndrome (DS) is one of the most common chromosomal abnormalities. Children with DS have an increased risk of developing acute lymphoblastic leukemia (ALL). Standard therapy is usually used to treat ALL in children with Down syndrome, but the outcome is worse than in the general population. The high toxicity of therapy is a particular problem.The purpose of the study – in this study we presents a comparative analysis of the results of therapy for children with DS and ALL (DS-ALL) who received therapy according to the ALL-MB 2008 and ALL-MB 2015 protocols.Materials and methods. The analysis included primary ALL patients, aged 1 to 18 years, who received therapy in Russian and Belarusian clinics participating in the Moscow–Berlin study from January 2008 to December 2020. To analyze the treatment results of DS-ALL patients, a “comparison group” was formed from all patients with ALL registered in the database, using the matched-pair method. Survival was calculated using the Kaplan–Meier method, toxicity analysis and clinical-genetic parameters were investigated using nonparametric statistical methods.Results. The results of therapy both among patients with DS-ALL who received therapy according to ALL-MB 2008 and ALL-MB 2015 in comparison with “sporadic” ALL (non-DS-ALL) are unsatisfactory. The event-free survival rate of patients with DS-ALL in the ALL-MB 2008 group was 61 ± 7 % versus 85 ± 4 % among non-DS-ALL (p = 0.001), in the ALL-MB 2015 group – 67 ± 7 % versus 84 ± 4 % respectively. Overall survival in the ALL-MB 2008 group was 70 ± 7 % in children with DS versus 88 ± 4 % in non-DS (p < 0.001), in the ALL-MB 2015 group – 78 ± 6 % versus 92 ± 3 % respectively (p < 0.001). The risk of therapy-related death was higher in patients with DS: 20.6 ± 6.1 % versus 4.6 ± 2.2 %; p < 0.001 in the ALL-MB 2008 group and 18 ± 4.1 % versus 3.3 ± 1.3 %; p < 0.001 in the ALL-MB 2015 group, without a significant increase in the risk of relapse. The effectiveness of induction therapy among patients with DS treated according to ALL-MB 2008 versus children with DS-ALL treated according to ALL-MB 2015 was 80 % versus 92 % respectively (p = 0.018). The probability of achieving continuous complete remission was also lower in the ALL-MB 2008 group compared to ALL-MB 2015 – 57 % versus 75 %; p < 0.001 respectively. Thus, the results of treatment of DS-ALL according to the ALL-MB 2015 protocol were better than those according to the ALL-MB 2008.Conclusion. The results of therapy for patients with DS-ALL are still unsatisfactory today, this circumstance dictates the need for new approaches to optimize therapy. The main problem for these patients remains the high toxicity of therapy and the associated lethality. Further progress in the treatment of DS-ALL may be associated with the development of new approaches to concomitant therapy, the use of molecular-targeted drugs and immunotherapy, as well as with the study of the molecular genetic characteristics of this subgroup of patients.

21 April 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
YOYu. V. Olshanskaya
Yu. V. Olshanskaya
OSOlga Soldatkina
Olga Soldatkina
ENE. N. Nikitin
E. N. Nikitin
NTN. M. Timofeyeva
N. M. Timofeyeva
AAA. N. A.KAzakova
A. N. A.KAzakova
ЮРЮ. В. Румянцева
Ю. В. Румянцева
The detection of genetic markers associated with poor prognosis is crucial to the selection of an appropriate treatment plan for B-cell precursor acute lymphoblastic leukemia (BCP-ALL). A hypodiploid karyotype in patients with BCP-ALL has an unfavorable impact and serves as a criterion for the stratification of patients into a high-risk group. However, the survival rates of patients with a hypodiploid karyotype remain poor. Russian treatment protocols for childhood acute lymphoblastic leukemia do not include a hypodiploid karyotype in risk stratification criteria. In order to determine the prognostic value of a hypodiploid karyotype and the clinical characteristics of BCP-ALL in patients with a hypodiploid karyotype, we analyzed the survival rates of 2,700 patients included in a multicenter study. Our study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI of the Ministry of Healthcare of the Russian Federation. All patients underwent karyotyping and fluorescence in situhybridization (FISH) testing. A hypodiploid karyotype was detected in 27 patients. Eighteen out of 27 patients had a hypoploid clone (according to karyotyping results), 2 patients had a doubled near-haploid clone (according to karyotyping and FISH results); in 7 patients with a normal karyotype or in the absence of mitosis, hypodiploidy was determined only by FISH test. BCP-ALL with hypodiploidy is usually associated with increased WBC count at disease onset. The median WBC count in the study group was 24.2 (3.4–206.0) × 109/l vs 10.3 (0.2–1290.0) × 109/l in the control group. The number of patients with initial leukocytosis 30 × 109/l in the study group was significantly lower than in the control group (p 0.062). Remission was achieved in 26/27 patients. The event-free survival rates in patients with hypodiploidy were significantly lower than in those without hypodiploidy: 50 ± 11% vs 72 ± 8% (p 0.0001). The overall survival was 64 ± 10% and 90 ± 1%, respectively (p 0.0001). The cumulative incidence of relapse in patients with a hypodiploid karyotype was higher (42.6 ± 10.9%) than in the controls (22.3 ± 8.1%) (p 0.0001). The patients who received more intense treatment for intermediate- and high-risk groups showed better survival rates than those in the standard-risk group: 62 ± 13% vs 40 ± 15% (р= 0.59); the cumulative incidence of relapse according to the risk group was 26.4 ± 12.1% and 60 ± 16.9%, respectively (р= 0.19).The highest risk of relapse was observed in a group that included patients with near-haploidy and low hypodiploidy (26–39 chromosomes; 52.9 ± 14.4%). The event-free survival in this group was 36 ± 13%. The results of treatment of patients with BCP-ALL and hypodiploidy according to the national guidelines turned out to be comparable to the international ones. Patients with BCP-ALL and hypodiploidy should be initially stratified to the most intense treatment arm. In order to identify patients with hypoploidy, standard karyotyping is required; where needed, it can be supplemented by FISH analysis

20 December 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
APAlexander popov
Alexander popov
GTG. A. Tsaur
G. A. Tsaur
YRYu. V. Rumiantseva
Yu. V. Rumiantseva
OBO. I. Bydanov
O. I. Bydanov
TVT. Yu. Verzhbitskaya
T. Yu. Verzhbitskaya
ТВТ. Ю. Вержбицкая
Т. Ю. Вержбицкая
The achievement of remission at the end of induction (EOI) chemotherapy in patients with acute lymphoblastic leukemia (ALL) is the key parameter of treatment effectiveness evaluation. The aim of the study – defining complete remission by multicolor flow cytometry (MFC) and bone marrow (BM) cytomorphology (CM) at the EOI chemotherapy in children with B-lineage ALL. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included patients of “ALL-MB 2008” and “ALL-MB 2015” trials for whom minimal residual disease (MRD) was evaluated by MFC at the EOI simultaneously with CM BM investigation. Less than 5% blasts in BM and MRD 1% were established as the remission achievement criteria for CM and MFC respectively. The study group included 1498 children aged from 1 to 18 years (median age was 4 years and 11 months) with B-cell precursor ALL. The overall concordance of MFC and CM was found to be 96.1% (1440 of 1498 patients). In 36 (2.4%) children with MRD ≥ 1%, M1 BM status was observed. In contrast, in 22 (1.5%) patients with M2/M3 BM status by CM, MRD value was below 1%. Treatment outcome was analyzed in 522 patients of “ALL-MB 2008” trial. Children with M2/M3 BM, as well as with MRD ≥ 1% demonstrated dramatically inferior outcome, in comparison to those who achieved remission. The presence of at least one of the mentioned criteria (M2/M3 status by CM or MRD ≥ 1% by MFC) defined a group of 23 (4.4%) patients with very low event-free survival (34.9%, standard error 11.0%) and very high cumulative incidence of relapse (56.4%, standard error 12.0%). For the evaluation of remission achievement, MFC and CM should be applied simultaneously at the EOI. High leukemic burden found by any of these methods is the clear definition of induction failure. MRD detection at the EOI should be implemented in any modern treatment protocol as an obligatory stage of treatment response monitoring and final risk group stratification. Considering the crucial importance of the MRD detection results, this study must be performed only in the reference laboratories of the study groups.

8 April 2025 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
AKA. I. Karachunskiy
A. I. Karachunskiy
SLS. N. Lagoyko
S. N. Lagoyko
YRYu. V. Rumyantseva
Yu. V. Rumyantseva
LZL. I. Zharikova
L. I. Zharikova
OBO. I. Bydanov
O. I. Bydanov
GNG. A. Novichkova
G. A. Novichkova
This study investigated the efficacy and safety of the use of pegaspargase on day 3 of remission induction in children with intermediate-risk acute lymphoblastic leukemia (ALL). The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The study included 1470 children with intermediate-risk ALL. The patients were randomized into two groups to receive pegaspargase (1000 IU/m²) on day 3 of induction or not to receive pegaspargase. There was no significant difference in event-free survival between the pegaspargase and non-pegaspargase groups. In the pegaspargase group, the cumulative incidence of relapse was significantly lower (8.3% vs. 13.1%; p = 0.02). A particularly notable reduction in relapse incidence was seen in the patients with B-lineage ALL, especially in those over 10 years of age. There were no significant differences in early mortality, overall survival, and incidence of hypersensitivity reactions between the two groups. The administration of pegaspargase on day 3 of induction in the patients with intermediate-risk ALL significantly reduced relapse rates without increasing toxicity. This finding led to the inclusion of pegaspargase in the updated ALL MB 2015 protocol, which is now routinely used in the treatment of children and adolescents with ALL in Russia.